Precision Biosciences (DTIL) Assets Average (2019 - 2026)

Precision Biosciences (DTIL) has 8 years of Assets Average data on file, last reported at $149.2 million in Q1 2026.

• Assets Average for Q1 2026 came in at $149.2 million, up 14.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.2 million (up 14.38% YoY), and the FY2025 annual result was $145.4 million, down 1.81% from the prior year.
• Assets Average rose to $149.2 million in Q1 2026 per DTIL's latest filing, from $124.0 million in the prior quarter.
• Over five years, Assets Average peaked at $284.4 million in Q3 2022 and troughed at $101.2 million in Q3 2025.
• A 5-year average of $176.3 million and a median of $172.3 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average gained 24.4% in 2022, then plunged 39.17% in 2023.
• A 5-year view of Assets Average shows it stood at $255.0 million in 2022, then sank by 36.43% to $162.1 million in 2023, then retreated by 10.64% to $144.8 million in 2024, then slipped by 14.4% to $124.0 million in 2025, then rose by 20.32% to $149.2 million in 2026.
• Business Quant data shows DTIL's Assets Average at $149.2 million in Q1 2026, $124.0 million in Q4 2025, and $101.2 million in Q3 2025.